Trials / Completed

CompletedNCT00549965

Satisfaction and Compliance of Risedronate in PMO

A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 202 (actual)

Sponsor: Sanofi · Industry
Sex: Female
Age: 55 Years – 80 Years
Healthy volunteers: Not accepted

Summary

Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women. Secondary objectives are to measure compliance (50 % drug taken), and persistence.

Conditions

Osteoporosis, Postmenopausal

Interventions

Type	Name	Description
DRUG	Risedronate Sodium

Timeline

Start date: 2003-10-01
First posted: 2007-10-26
Last updated: 2007-10-30

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00549965. Inclusion in this directory is not an endorsement.